Skip to Main Content

Paper Details

MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
Neuro Oncol
28
2022
Author NameAffiliation
Jaishri O BlakeleyJohns Hopkins University
Jason FangusaroChildren's Hospital of Atlanta, Emory University and the Aflac Cancer Center
Bruce D GelbIcahn School of Medicine at Mount Sinai
Bruce D GelbIcahn School of Medicine at Mount Sinai
Darren HargraveGreat Ormond Street Hospital for Children
Mignon L LohBenioff Children's Hospital, University of California San Francisco
Roger J PackerCenter for Neuroscience and Behavioral Medicine and Center for Cancer and Blood Disorders, Children's National Hospital
Roger J PackerCenter for Neuroscience and Behavioral Medicine and Center for Cancer and Blood Disorders, Children's National Hospital
Brigitte C WidemannNational Cancer Institute
Michael J FisherThe Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine
  • 1 - 10

Datasets